

Amendments to the Specification

On page 1, please insert a new paragraph before the first paragraph as follows:

This is a divisional of application Serial Number 10/389,578, filed March 17, 2003, now US Patent No. 6,713,497.

On page 4, please amend the sentence beginning on line 20 to read as follows:

A preferred GABAergic drug is gamma vinyl GABA (GVG). GVG is represented by the compound 4-amino-hex-5-enoic acid, and is sold under the product names ~~Vigabatrin®~~ VIGABATRIN® and ~~Sabril®~~ SABRIL® by Hoechst-Marion Roussel.

On page 5, please amend the paragraph beginning on line 13 to read as follows:

As used herein GVG includes the racemic compound or mixture which contains equal amounts of S(+)-gamma-vinyl GABA, and R(-)-gamma-vinyl GABA. This racemic compound of GVG is available as ~~Vigabatrin®~~ VIGABATRIN® from Hoechst Marion Roussel and can be obtained from Marion Merrell ~~Merrell~~ Dow of Cincinnati, Ohio.

On page 10, please amend the paragraphs beginning on line 13 to read as follows:

A composition containing gabapentin will include gabapentin in an amount from about 500mg to about 2g/day. Gabapentin is available as ~~Neurontin®~~ NEURONTIN® from Parke-Davis in the United States.

A composition containing valproic acid will include valproic acid in an amount from about 5mg/kg to about 100mg/kg/day. Valproic acid is available as ~~Depakene®~~ DEPAKENE® from Abbott in the United States.

A composition containing topiramate acid will include topiramate in an amount from about 50mg to about 1g/day is available as ~~Topamax®~~ TOPAMAX® from McNeil in the United States.

On page 11, please amend the paragraph beginning on line 1 to read as follows:

A composition containing progabide will include progabide in an amount from about 250mg to about 2g/day. Progabide is available as Gabrene® GABRENE® from Synthelabo, France. The chemical formula of progabide is $C_{17}H_{16}N_2O_2$.

Please amend the paragraph on page 15 as follows:

ABSTRACT OF THE INVENTION

The invention provides a method for treating visual field defects in a mammal in need thereof by administering an effective amount of vitamin B6 to the mammal. ~~Novel~~ The invention also provides compositions containing a GABAergic drug and vitamin B6 ~~are also provided.~~